Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
Study IPI-504-15 is a Phase 1b/2 clinical trial to evaluate the safety and efficacy of
retaspimycin HCl (IPI-504) plus everolimus in patients with KRAS mutant Non-small Cell Lung
Cancer (NSCLC).